R
ecombinant human bone morphogenetic protein-2 (rhBMP-2) is widely used as an alternative to iliac crest bone graft (ICBG) to promote fusion in spinal surgery (1, 2) . Since the U.S. Food and Drug Administration (FDA) approved rhBMP-2 for anterior lumbar interbody fusion (ALIF) surgery (3) , its use has grown rapidly, including off-label indications (2, 4) . A review of publicly available data suggesting that the risk for adverse events is 10 to 50 times higher than reported in trial publications (5) raised concerns about the safety of rhBMP-2.
The Yale University Open Data Access (YODA) Project team invited Medtronic (Minneapolis, Minnesota) to provide full data from all of its trials of rhBMP-2 to allow independent reanalysis. The project team subsequently invited proposals to undertake independent evaluation and funded the Centre for Reviews and Dissemination and 1 other group to do so, thus enabling meta-analysis of individual-participant data (IPD), which is regarded as a "gold standard" approach to evidence synthesis.
We embedded our IPD meta-analysis within a systematic review and sought to examine all relevant evidence. Investigation of comparative effectiveness was restricted to randomized, controlled trials (RCTs). In addition, to investigate the safety of rhBMP-2, we sought all observational studies of its use in spinal surgery that reported adverse events. Findings of our investigation of reporting bias are presented in our full report and have been submitted for publication elsewhere (5a). tion (rhBMP-2 concentration, 1.5 g/L) and unlicensed AMPLIFY (rhBMP-2 concentration, 2 g/L) and biphasic calcium phosphate (BCP) formulations. For supporting analyses of safety, we included all studies of more than 10 adult participants that compared rhBMP-2 with any other spinal fusion technique and reported adverse events.
Our reanalysis of the Medtronic data was done in the context of a full systematic review. We performed a systematic literature search of the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, and Science Citation Index in January 2012 and automated "current awareness" searches up to June 2012 to identify eligible studies not provided by Medtronic. We also searched ClinicalTrials.gov to identify ongoing or unpublished randomized trials and published a call for evidence. Detailed search strategies are provided in Appendix 1 (available at www.annals.org).
One researcher collated IPD from across the SAS data files (SAS Institute, Cary, North Carolina) provided by Medtronic, and a second researcher checked the process. The data were checked for completeness, internal consistency, improbable values, and balance of patient characteristics across treatment groups (see Appendix 2, available at www.annals.org, for details). Three researchers independently working in pairs performed study selection and data extraction from published reports. Disagreements were resolved by discussion or by referring to the third researcher. We assessed risk of bias by using the Cochrane Collaboration's "risk-of bias" tool in the RCTs and a modified form of the Newcastle-Ottawa Scale for nonrandomized studies (8, 9 ) (see Appendix 2 for details). Risk of bias was assessed by at least 2 researchers independently, with disagreements resolved by discussion.
Effectiveness Analysis
Our prespecified primary outcomes were those likely to be important to patients. The Oswestry Disability Index (ODI) and Neck Disability Index for cervical spinal surgery measure lower back and neck pain, respectively, on a scale from 0% (no pain) to 100% (extreme pain). The Short Form-36 (SF-36) Physical Component Summary (PCS) assesses pain and physical function on a scale from 0% (worst) to 100% (best). Medtronic also provided data on back and leg pain, which were measured on a scale from 0 (no pain) to 20 (extreme pain). Spinal fusion was assessed as success or failure according to Medtronic's radiographic definition, which required evidence of bridging trabeculae, no evidence of motion (Ͻ3-mm difference in translation and Ͻ5-degree difference in angular motion), and no evidence of radiolucency. We analyzed these outcomes at 6 weeks and 3, 6, 12, and 24 months after surgery. We did not analyze the limited data that were available for longer follow-up times for few participants.
We also considered 4 secondary outcomes: duration of hospital stay, operating time, successful return to work or usual activity, and use of pain medication.
Statistical Methods
Appendix 2 provides details of statistical methods and analyses. In the analyses of effectiveness for continuously distributed outcomes (such as ODI score), we calculated mean differences between treatment groups in the change in score from preoperative values. For dichotomous outcomes (such as successful fusion), we calculated relative risks (RRs). Both were calculated separately for every trial at every time point. We then used standard random-effects meta-analytic techniques (10, 11) to combine effect estimates across trials. Separate meta-analyses were done for each of the specified time points. Linear and logistic random-effects regression models were used to combine all data from all trials in "1-stage" meta-analyses as sensitivity analyses (12, 13) . We used multiple imputation to explore the influence of missing observations.
Heterogeneity was assessed in all meta-analyses by using the Higgins I 2 statistic (14) and the Cochran Q test. We performed a subgroup analysis (stratified by trial) to examine whether effects varied according to the type of spinal surgery or by rhBMP-2 formulation (INFUSE or AMPLIFY). We investigated whether patient-level factors (age, sex, smoking, alcohol consumption, body mass index, diabetic status, and history of spinal surgery for back pain) were associated with the effectiveness of rhBMP-2 surgery by using a 1-stage random-effects regression model (12) that included interaction terms between patient-level factors and treatment.
Safety Analysis
We examined numbers of adverse events, including cancer, provided in the IPD according to the Medtronic classifications of adverse events. Medtronic did not provide case report forms, but summaries of cases were given for most patients in the clinical study reports. A full clinical assessment of these narratives was beyond the scope of this project, but checks in 1 trial (Inter Fix PLIF [15] ) showed that the Medtronic classifications of events seemed appropriate. To our knowledge, these data represent all adverse events that occurred during the follow-up periods of these trials. Because the number of specific adverse events in most trials was generally small, we used 1-stage randomeffects logistic regression meta-analysis models (13) to analyze these data (see Appendix 2 for model details). Results of these analyses are presented as odds ratios.
We extracted data on number of adverse events from other published studies that compared spinal fusion surgery using rhBMP-2 with ICBG and other comparators in at least 10 adult participants, as specified in our protocol.
Role of the Funding Source
This review was funded by the YODA Project, which provided the IPD for and other materials relating to the Medtronic trials but was not involved in the analyses of these data or in the production of this paper. There was no direct contact with Medtronic or the other evaluation team. Our full report to the YODA Project is publicly available and examines a wide range of issues around the effectiveness and safety of rhBMP-2 in spinal surgery (16, 17).
RESULTS
The YODA project team provided IPD from 17 Medtronic trials. Eleven of these were RCTs comparing rhBMP-2 with ICBG surgery and were eligible for inclusion in our principal evaluation of effectiveness. Of the others, 4 were single-group trials of rhBMP-2 and 1 (7) used a different comparator. We included these only in our supporting consideration of adverse events. We did not consider 1 trial that was stopped early after recruiting only 3 patients. Figure 1 shows search results. In addition to the trials supplied by Medtronic, we identified 2 eligible randomized trials not conducted by Medtronic that compared rhBMP-2 with ICBG surgery. We requested IPD from the authors and obtained them from 1 study (18) . Data from the other trial, which involved 40 patients having singlelevel bilateral posterior lateral interbody fusion, were unavailable (19). This trial reported 100% fusion in both groups and no difference in back pain or ODI score at 12 months and therefore these published aggregate data could not contribute to our analyses. We identified 1 ongoing trial for which recruitment had been suspended, but we could not include it because it had not been closed (20).
Our IPD meta-analysis was based on data from 1302 patients in 11 Medtronic RCTs that compared rhBMP-2 with ICBG surgery, as well as data from 106 participants in 1 additional RCT (18) ( Table 1) .
Appendix Table 1 (available at www.annals.org) provides details of publications associated with each Medtronic trial. However, our analyses used the supplied IPD rather than data reported in these publications.
For all of the included trials, data on all pain outcomes were available at all time points from 6 weeks to 24 months. Data on spinal fusion were available for all Medtronic trials except the LT-CAGE pilot trial (31) at all times from 6 months onward. The trial by Glassman and colleagues (18) provided fusion data in a different format and is not included in these analyses. Appendix Table 2 (available at www.annals.org) summarizes the levels of missing data for the main pain and fusion outcomes. At 24 months after surgery, outcome data were not available for approximately 15% of participants. Our assessment of risk of bias was the same for all Medtronic trials. Randomization and allocation concealment procedures were adequate for all trials. Neither patients nor physicians were blinded to the treatment received, and all pain and function outcomes were patientassessed, so there was a potential for bias in these outcomes. Successful fusion was assessed by researchers blinded to the treatment received. Figure 2 shows results of meta-analyses across the 12 RCTs for 4 pain outcomes (the SF-36 PCS also incorporates an assessment of physical function). From 6 months after surgery onward, the use of rhBMP-2 generally achieved greater pain reduction (from preoperative values) than did ICBG. Among rhBMP-2 recipients, the ODI score was approximately 3.5 percentage points better (mean difference, Ϫ3.48 percentage points [95% CI, Ϫ6.47 to Ϫ0.49 percentage points]; I 2 ϭ 38%) and back pain was better by more than 1 point on the 20-point scale used (mean difference, Ϫ1.58 [CI, Ϫ2.65 to Ϫ0.51]; I 2 ϭ 44%) at 24 months after surgery. The SF-36 PCS score was 1.93 percentage points higher for rhBMP-2 recipients (CI, 0.63 to 3.22 percentage points; I 2 ϭ 0%) at 24 months. We found no evidence of a difference in leg pain reduction between treatment groups (mean difference, Results of the 1-stage linear regression meta-analysis models of pain outcomes were almost identical to the results presented earlier, as were those from models that used multiple imputation of missing pain data (see Appendix Figure 2 , available at www.annals.org). Figure 3 shows a forest plot for successful fusion 24 months after surgery, at which time rhBMP-2 increased fusion rates by 12% (RR, 1.12 [CI, 1.02 to 1.23]). Increased fusion rates were also identified at 6 months (RR, 1.20 [CI, 1.00 to 1.44]) and 12 months (RR, 1.11 [CI, 1.00 to 1.22]) after surgery. However, we found substantial heterogeneity of the RR for successful fusion across trials (I 2 ϭ 97%, 80%, and 76% at 6, 12, and 24 months, respectively).
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Results from the 1-stage logistic regression metaanalysis model for successful fusion were almost identical to the results presented earlier, as were those from models that used multiple imputation of missing fusion data.
Investigation by Surgical Approach
We performed subgroup analyses to investigate whether the effectiveness of rhBMP-2 varied among patients who had anterior lumbar fusion, posterior lumbar fusion, or anterior cervical fusion ( Table 1) . Appendix Figure 3 (available at www.annals.org) shows the results of these analyses for ODI score and successful fusion 24 months after surgery. A test for heterogeneity showed moderate evidence of a difference between surgery types for ODI score (P ϭ 0.065), but this was primarily due to the large benefit of rhBMP-2 on the Neck Disability Index score observed in the single small cervical surgery trial (n ϭ 23). Excluding this trial resulted in no clear difference in the effectiveness of rhBMP-2 between anterior or posterior approaches (P ϭ 0.171). We found no evidence of a difference in the RRs for successful fusion (P ϭ 0.88) or any other outcome at 24 months across surgery types. Evidence of interactions between rhBMP-2 and the patient-level factors (age, sex, smoking, alcohol consumption, body mass index, diabetic status, and history of spinal surgery) was generally lacking-that is, each factor benefited from rhBMP-2 to the same extent. One possible exception was that, for persons with a previous spinal surgery, there was no difference in the effectiveness of rhBMP-2 and ICBG at reducing ODI score or improving fusion rates. Given the number of analyses done, this may be a chance finding. These results are available in our full report (17).
Secondary Outcomes
We found no evidence of difference in duration of hospital stay (mean difference, Ϫ0.15 days [CI, Ϫ0.33 to 0.03 days]) or that rhBMP-2 surgery increased the probability of returning to work or usual activity earlier compared with ICBG (RR at 24 months, 1.01 [CI, 0.88 to 1.17]). Using rhBMP-2 shortened operating times by 21 minutes (CI, 15 to 27 minutes) (Appendix Figure 4 , available at www.annals.org) from an average of 135 minutes. We found no evidence that analgesic use differed between the rhBMP-2 and ICBG groups at any time (Appendix Figure 5 , available at www.annals.org).
We investigated the association between successful fusion and change in pain score by comparing the mean difference in pain at 24 months after surgery with the RR for successful fusion at the same time point for each of the 4 pain outcomes (ODI score, SF-36 PCS score, back pain, and leg pain) (Appendix Figure 6 , available at www.annals .org). We found no evidence of a consistent relationship between improvements in fusion due to rhBMP-2 and improvements in pain or function. If successful fusion resulted in reduced pain, we would expect trials that showed higher fusion rates with rhBMP-2 to show greater improvement in pain scores, but this did not seem to be the case. In particular, trials where fusion was less common in the rhBMP-2 recipients (Inter Fix ALIF pilot [27] and BCP U.S.
[32]) still showed a benefit of rhBMP-2 in terms of improved SF-36 PCS score. The BCP U.S. trial also showed a benefit of rhBMP-2 on ODI score and back pain. Therefore, the apparent small benefits of rhBMP-2 in pain reduction do not seem to be due to increased fusion rates.
Safety
All Medtronic trials provided data on adverse events at all specified time points and also at or shortly after (that is, up to 4 weeks after) surgery. Because reporting of adverse events in the trial by Glassman and colleagues (18) was not consistent with that in the Medtronic trials, it was not included in these analyses; however, the data are included in our full report (17).
We note that pain was reported as an adverse event in the Medtronic IPD as well as being assessed as an effectiveness outcome using the pain scales discussed earlier. The reasons for this were not clear, but for completeness, we analyze pain reported as an adverse event, particularly because pain immediately after surgery was not recorded on the pain scales-its presence or absence was recorded only as an adverse event. 
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ALIF ϭ anterior lumbar interbody fusion; BCP ϭ biphasic calcium phosphate; ICBG ϭ iliac crest bone graft; PLIF ϭ posterior lumbar interbody fusion; rhBMP-2 ϭ recombinant human bone morphogenetic protein-2; RR ϭ relative risk. Figure 4 shows the results of the 1-stage meta-analyses for adverse events across the 11 Medtronic RCTs at or shortly after surgery. Risks for arthritis and bursitis, implant-related events, neurologic events, other pain, retrograde ejaculation, wound complications, and vascular events increased by at least 50% among rhBMP-2 recipients. Because there were few events, CIs were wide and findings were inconclusive. For back and leg pain, we found clear evidence of a higher incidence among rhBMP-2 recipients (odds ratio, 1.92 [CI, 1.14 to 3.25]; P ϭ 0.004). Appendix Figure 7 (available at www.annals .org) shows the results of the 1-stage meta-analyses for adverse events over all times up to 24 months after surgery. As in the analysis in Figure 4 , results were generally inconclusive.
Appendix Figure 8 (available at www.annals.org) shows the results of meta-analyses for 4 key adverse event categories (implant-related, infections, neurologic, and any pain) across all periods. Events were uncommon, so findings are mostly inconclusive. The only clear evidence of a difference was for pain at or shortly after surgery, which was more common in rhBMP-2 recipients (odds ratio, 1.78 [CI, 1.06 to 2.95]; P ϭ 0.007). This contrasts with the results seen in the analyses of ODI score, SF-36 PCS score, and back pain in the effectiveness analyses, where pain reduction was greater in the rhBMP-2 recipients from 3 months after surgery onward. Table 2 summarizes the cancer cases observed in the 11 Medtronic RCTs, 5 of which observed at least 1 case. It excludes preexisting cancer but includes 3 cases in the LT-CAGE open pivotal trial (33) that were identified during extended follow-up of only the rhBMP-2 recipients. However, these 3 cases were not included in the quantitative analyses because this would have biased against rhBMP-2 because any equivalent cases occurring in the ICBG group had not been sought. A 1-stage random-effects metaanalysis model found that cancer was nearly twice as common among rhBMP-2 recipients (RR, 1.98 [CI, 0.86 to 4.54]), but the 95% CIs were consistent with risk in rhBMP-2 recipients being anywhere from 14% lower to 454% higher. The absolute risk for cancer was low (3% in rhBMP-2 recipients). A forest plot for the equivalent 2-stage analysis is shown in Figure 5 (RR, 1.84 [CI, 0.81 to 4.16]). The RR for cancer was similar across trials. In particular, the RR for cancer in the AMPLIFY trial (34, 35), which used a different preparation of rhBMP-2 at a higher dose, was no greater than in trials that used INFUSE (P ϭ 0.82). We note that in addition to the 3 cancer cases identified during additional follow-up, 3 cases were seen among rhBMP-2 recipients in the Maverick trial (7) and 2 were seen in a single-group Medtronic trial (36 -38). These were not included in our analyses because neither trial had an ICBG comparator.
Cancer
Adverse Events Reported in the Literature
We identified 35 observational studies of at least 10 adult patients (in 43 publications) that reported adverse effects of rhBMP-2. There were 14 studies of posterior lumbar fusion, 5 of anterior lumbar fusion, 10 of cervical fusion, and 8 that used multiple spinal fusion procedures. These studies used various spinal fusion techniques as controls, including ICBG, local bone graft, allograft, and bone marrow aspirates. Other than the Medtronic Maverick trial (7), we did not have IPD from any of them. The studies are summarized in Appendix Table 3 (available at www .annals.org). Quality assessment found that all of the studies included patients who were representative of those likely to receive treatment in practice and clearly established exposure to treatment. However, most made no attempt to match or control for potential confounding factors, and data on the comparability of the treatment groups were generally unreported or limited. Given the heterogeneity of these studies and their potential for bias, we did not meta-analyze these data.
Despite the methodological issues, we found evidence suggestive of higher rates of particular adverse events among rhBMP-2 recipients (Figure 6 ). Among studies reporting at least 1 event, heterotopic bone formation (reported in 5 studies) was more common among rhBMP-2 recipients, although whether this led to any clinical consequences for these patients was unclear. Leg pain and radiculitis (4 studies) seemed to be more common, as had been observed in the Medtronic trials. Osteolysis was more common, but only 2 studies reported on this event. Dysphagia (6 studies) seemed to be more common among rhBMP-2 recipients having cervical spinal surgery, although results of these studies were inconsistent. Comer and colleagues (39) compared 4 consecutive-patient cohorts undergoing ALIF with or without rhBMP-2 and reported a higher rate of retrograde ejaculation among rhBMP-2 recipients (6.3% vs. 0.9%; P ϭ 0.001). Further adverse event outcomes were examined in our full report.
DISCUSSION
Our principal analyses were based on data from 1408 individual participants in 11 eligible RCTs, including all trials sponsored by Medtronic (published and unpublished) and 1 additional trial. We found the randomization 
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The number of cancer cases is the total number occurring during the 2-y follow-up. Details on the Medtronic trials are available in Appendix Table 1 , available at www.annals.org. BCP ϭ biphasic calcium phosphate; ICBG ϭ iliac crest bone graft; rhBMP-2 ϭ recombinant human bone morphogenetic protein-2; RR ϭ relative risk.
procedures to be adequate in all trials, but participants were not blinded to treatment. Although assessment of some outcomes, such as radiologic assessment of fusion, was blinded, patient-reported outcomes related to pain were not. Follow-up was reasonably complete up to our final analysis time point of 24 months. Although there is some potential for bias associated with patient-reported outcomes, in general, we consider the body of evidence for comparative effectiveness to be strong. We found clear evidence that rhBMP-2 improves rates of fusion compared with ICBG; however, the Medtronic definitions of fusion that we used may have been stringent given that only 69% of ICBG recipients achieved fusion within 24 months, which is lower than would be expected generally. Inconsistency across trials was high, with large I 2 values at all time points.
We also found that rhBMP-2 improves back pain and quality of life compared with ICBG at between 6 and 24 months after surgery. However, these improvements in pain fall below previously described, clinically meaningful thresholds (estimated as between 4 and 17 percentage points for ODI score and Ն5.4 points for SF-36 PCS [40, 41]).
In general, successful fusion and pain reduction do not seem to be strongly correlated. Trials with higher fusion rates for rhBMP-2 did not also achieve greater pain reduction. In the trials with lower fusion rates among rhBMP-2 recipients, pain reduction was still greater among these patients. It therefore seems that either rhBMP-2 surgery has an effect on pain beyond that from fusion-which seems medically unlikely-or the interpretation of pain was biased. Because participants were not blinded to the treatment received or their fusion status, they may have reported exaggerated benefits of the "new" treatment, thus biasing assessment in favor of rhBMP-2.
In contrast, the analysis of adverse events reported in the IPD showed an increased risk for pain associated with rhBMP-2 in the immediate postsurgical period. Although this may seem to contradict the finding that rhBMP-2 reduces pain from 6 months onward, rhBMP-2 surgery may lead to increased pain shortly after surgery but reduced pain in the longer term.
The IPD also indicate that rhBMP-2 may be associated with an increased risk for cancer, with nearly double the number of new cancer cases compared with ICBG recipients. The overall absolute risk for cancer is low in both groups, however, so whether this increased risk is genuine is uncertain, but it is consistent with the literature suggesting a possible link between BMP and cancer (42). Adverse event data in the literature raise concerns that rhBMP-2 may increase the risk for heterotopic bone formation, osteolysis, radiculitis, and retrograde ejaculation. However, these findings should be interpreted cautiously because they are based on only published nonrandomized studies, most of which provided little information about the comparability of groups.
Our review differs from the existing review (5) in that we had access to more extensive and detailed data than did Carragee and colleagues, who used aggregate data extracted from publications of industry-sponsored trials and publicly available FDA summaries and public meeting documents. The FDA materials seem to provide incomplete outcome data from a subset of trials evaluating rhBMP-2. We analyzed IPD from all Medtronic-sponsored trials regardless of whether they had been published or submitted to the FDA. This review included the licensed INFUSE preparation of rhBMP-2 and the unlicensed AMPLIFY and BCP preparations, which use a higher dose of rhBMP-2. We found no evidence of a difference in effectiveness, safety, or cancer risk between licensed and unlicensed preparations.
The use of rhBMP-2 in spinal fusion surgery increases the likelihood of successful fusion at up to 24 months, but this does not seem to translate into a clinically significant reduction in pain. The small improvements in fusion and in the level of pain reduction, which manifest after 6 months, also seem to come at the expense of more frequent pain in the immediate postoperative period and, possibly, an increased number of cancer cases. We believe that it is important that clinicians explain these findings to patients so that they can make informed choices about the type of surgery they would prefer.
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Disclaimer: This study used data obtained from the YODA Project that included 17 clinical trials of rhBMP-2 funded by Medtronic. The analysis, interpretation, and reporting of these data were completed independently on an unrestricted basis, are solely the responsibility of the authors, and do not necessarily represent the official views of the YODA Project. #14 #13 AND #6 #13 #12 OR #11 OR #10 OR #9 OR #8 OR #7 #12 Topicϭ("fusion cage") #11 Topicϭ((lumbar or cervical or posterior or anterior or lumbosacral or transforminal or posterolateral) NEAR/3 fusion*) #10 Topicϭ("lumbar interbody arthrodesis") #9 Topicϭ(spondylodes*) #8 Topicϭ(spondylosyndes*) #7 Topicϭ(spine or spinal) #6 #5 OR #4 OR #3 OR #2 OR #1 #5 Topicϭ(infuse or amplify) #4 Topicϭ(rh-bmp or rh-bmp2 or rh-bmp-2) #3 Topicϭ(rhbmp or rhbmp2 or rhbmp-2) #2 Topicϭ(bmp or bmp2 or bmp-2) #1 14,240 Topicϭ(("bone morphogen*" or osteogen* or osteoinduct*) NEAR/1 (protein* or factor* or polypeptide* or "poly-peptide*")) Similar searches were performed in PubMED, DARE (Database of Abstracts of Reviews of Effects), HTA, Biosis Previews, and Toxfile.
Call for Evidence Systematic Review of Bone Morphogenic Protein-2 (rhBMP-2) for Spinal Fusion
The Centre for Reviews and Dissemination (CRD) is undertaking a systematic review and individual participant data (IPD) meta-analysis of the comparative effectiveness of rhBMP-2 (marketed as INFUSE) for spinal fusion. The review has been commissioned by the Yale University Open Data Access (YODA) initiative as part of an overarching project to systematically review the safety and effectiveness of rhBMP-2, including reanalysis of IPD that have been made available to Yale on an unrestricted basis by the manufacturer (Medtronic Inc.). YODA aims to improve access to patient-level data from clinical trials and provide independent, scientifically rigorous, objective, and fair analyses of such data.
CRD will undertake a comprehensive and rigorous systematic review and meta-analysis of individual participant data (IPD) of all relevant randomised controlled trials that have compared rhBMP-2 with standard bone graft therapy.
We will include all relevant randomised controlled trials irrespective of whether conducted by the manufacturer or not, and irrespective of whether published or not. We are therefore interested in hearing from anyone who has conducted, or is aware of, unpublished or partially published research in this area. For example, trials which have been presented at conferences but not fully reported elsewhere.
We are currently aware of 17 trials funded by the manufacturer and have searched the published literature but welcome any information regarding further unpublished research. If you know of any such trials please contact [CRD details deleted]. Link to CRD project page: www.york.ac.uk/inst/crd/projects_in _progress.cfm.
Link to YODA page: http://medicine.yale.edu/core/projects /yodap/index.aspx
APPENDIX 2: METHODS
Data Sources Used
Analyses of efficacy were restricted to RCTs in spinal fusion surgery that compared rhBMP-2 with conventional ICBG surgery. Single-group trials of rhBMP-2 or trials with comparators other than IBCG were excluded.
One trial (rhBMP-2/BCP US pilot RCT) had 2 rhBMP-2 groups using different fixation procedures. Only the primary group was used in these analyses. The second rhBMP-2 group (consisting of 11 patients) was combined with the first in sensitivity analyses (not presented in this paper).
We performed all analyses using the patient-level data supplied by Medtronic and from Glassman and colleagues' (18) trial. Although intention-to-treat analyses were intended, this was not possible because many randomly assigned patients withdrew before surgery; therefore, no outcome data were available for them.
Outcomes of Interest Primary Outcomes
Disease-specific pain and functionality: ODI or Neck Disability Index scores for cervical spinal surgery; this measures lower back (or neck) pain on a scale from 0% (no pain) to 100% (extreme pain).
SF-36 PCS score, which assesses both pain and physical function on a scale from 0% (worst) to 100% (best).
Back and leg pain; both measured on a scale from 0 (no pain) to 20 (extreme pain).
Successful spinal fusion: Defined radiographically by Medtronic as requiring all of the following: evidence of bridging trabeculae, no evidence of motion (Ͻ3-mm difference in translation, Ͻ5-degree difference in angular motion), and no evidence of radiolucency.
Secondary Outcomes
Duration of hospital stay Operating time Successful return to work or usual activity Use of pain medication (not prespecified)
Safety Outcomes
We analyzed adverse events supplied by Medtronic that we considered to be potentially related to spinal surgery according to the categorizations provided in the Medtronic IPD. We also considered the following broad categories of adverse events: Pain: back, leg, lower extremity, arm, neck, and upper extremity pain Implant-related (hardware failure): displacement, breakage, loosening, malpositioning, and subsidence Infection Neurologic events: including numbness, tingling, "pins and needles" Cancer For adverse events not generally reported by Medtronic, we searched the wider literature and analyzed the following:
Leg pain (including radiculitis) Heterotopic bone formation Dysphagia (in cervical spinal surgery) Retrograde ejaculation Osteolysis (further outcomes were considered in our full report)
Patient-Level and Trial-Level Factors Affecting Effectiveness
We investigated how the effectiveness of rhBMP-2 might be influenced by trial-and patient-level characteristics. We investigated the following trial-level factors:
Spinal location of surgery (such as cervical or lumbosacral) Surgical approach (such as anterior lumbar fusion and posterior lumbar interbody fusion)
We also investigated the following patient-level factors: Previous spinal surgical interventions Age Sex Smoking status Diabetic status Body mass index
Time Points
These outcomes were analyzed at a range of different time points after surgery: 6 weeks and 3, 6, 12, and 24 months. Data on successful fusion were available only from 6 months after surgery onward. Data on adverse events were provided at these times and were also available and analyzed at or immediately after surgery (up to 4 weeks). For all trials, data were provided at all the described time points.
Data Management and Checking of IPD
Data were provided by Medtronic for each trial in a range of separate SAS-format data files according to the types of outcomes reported. From these, we collated individual-level data on all the available effectiveness outcomes at all the time points listed above.
Data from the single non-Medtronic trial (18) were provided as a single Excel (Microsoft, Redmond, Washington) spreadsheet.
For each trial for which IPD were provided, we checked the consistency of the data, both to ensure that the data as provided were valid and to check for errors in our data collation process. Data-checking procedures included the following:
Checking uniqueness and consistency of patient identification numbers Checking consistency of treatment allocation records Ensuring all demographic data (e.g., ages) were within plausible ranges
Ensuring all pain and function measurements (e.g., ODI score, SF-36 PCS) were within range, with no outliers Checking for balanced randomization in terms of age, sex, and other patient-level factors
Checking that summary scores (e.g., ODI score) agreed with the raw scores from each question from the questionnaire It was not possible to check judgments of fusion status without access to the raw radiologic data and a radiologist. However, if fusion status was assessed by blinded experts, any possible reporting bias or inconsistencies in judgment should be shared across both rhBMP-2 and the control groups. We have assumed that the assessments of spinal fusion provided by Medtronic are valid.
Quality Assessment and Risk of Bias
In addition to the data-checking procedures, we also assessed each randomized trial using the Cochrane risk-of-bias tool (8) . The Cochrane Collaboration developed this tool to assess aspects of trial design and conduct that have been demonstrated empirically to affect estimates of treatment effect. The tool does not address aspects of trial design that relate to applicability or generalizability.
The risk-of-bias tool covers 6 key areas of potential bias: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete outcome data, and selective reporting of outcomes. Each area was given a judgment of high risk of bias, unclear risk of bias, or low risk of bias, and a reason for each judgment was recorded in the main data extraction spreadsheet. We used the guidelines from the Cochrane Collaboration on what constituted high, low, and unclear risk of bias. Additional details were based on discussions with the clinical member of the team.
Two reviewers independently completed risk-of-bias assessments for all trials included in the efficacy analyses. Judgments were made for each type of outcome reported in the trials: fusion, patient-reported, and adverse events.
These decisions were based on the full trial protocols provided by Medtronic and the brief protocol provided by Glassman and colleagues.
To address incomplete outcome data, we used standard data-checking procedures described in the previous section to compare loss to follow-up in each group. We also checked that we had been given IPD for all outcomes that were listed in the trial protocols. We requested from Medtronic any available data for patients who were recruited but not reported in the trials. Some tabulated information was provided on why these patients did not undergo surgery and so were excluded from the IPD, but further data were unavailable. No postrandomization data had been collected for these individuals. We also checked loss to follow-up and missing outcome data (by treatment group) for main outcomes at each analysis time point.
Quality of the nonrandomized studies was assessed by using a domain-based approach, based on a modified version of the Newcastle-Ottawa scale (9) . However, we avoided scoring or assigning star values to the studies because doing so risks producing an uninformative summary score. Instead, we tabulated the relevant information for each of the following domains:
Representativeness of the exposed cohort (did the patients require spinal fusion surgery? Did they form a particular subgroup [for example, all smokers]?) Selection of the control group (were they drawn from the same source [for example, the same hospital or database]?) Ascertainment of exposure (given the nature of the topic, this was usually via a secure record in which the exposure to treatment was clearly known)
Outcome of interest not present at start of the study (was this explicitly checked for [for example, preexisting cancer]?)
Confounders or other factors used to match or controlled for in analysis Outcome assessment (independent/blind assessment, via secure medical record, self-report, or no details)
Follow-up (we considered adequacy of duration in relation to the specific adverse events reported and whether this was similar across the 2 groups)
Assessments were checked, with disagreements resolved by discussion and/or consultation with a third researcher.
Statistical Analysis
Our primary statistical method for estimating the efficacy of rhBMP-2 surgery for all the specified outcomes was to use standard 2-stage meta-analytic techniques (10, 11) . Individualpatient data from each trial were analyzed separately, using the same methods across trials, for all the efficacy outcomes. Separate meta-analyses were performed at each of the specified time points.
We also used a "1-stage" meta-analysis approach in some analyses, primarily as a sensitivity analysis to confirm the results of 2-stage analyses. These approaches are described in more detail below.
All main analyses used a complete-case approach in which participants with missing data were excluded from the analysis.
Estimates of Effect
Continuously Distributed Outcomes. For the continuously distributed outcomes (ODI, SF-36 PCS, back pain, leg pain), we assessed efficacy in terms of the mean difference in outcome between the rhBMP-2 and ICBG groups.
For each patient, the change in the score from baseline to the time point of interest was calculated. These were then averaged for each intervention in each trial and the difference in means within each trial calculated, and these mean differences were then combined across trials. This mean difference, along with its associated SE, was calculated for each trial.
Dichotomous Outcomes. For dichotomous outcomes (successful fusion, successful return to work, use of pain medication, cancer), we assessed efficacy in terms of the RR for the outcome between the rhBMP-2 and ICBG groups.
In the 1-stage random-effects meta-analyses, RRs could not be calculated because algorithms did not converge successfully (that is, they crashed). For these models, results were therefore calculated in terms of the odds ratio, with its corresponding 95% CI.
Two-Stage Meta-Analyses
We combined the effect estimates from each trial (mean difference or RR) across trials using a standard DerSimonianLaird random-effects meta-analysis to account for potential heterogeneity in effects across trials (55). Separate analyses were performed at each time point. We present the results as summary plots across all times. This is called a "2-stage" approach because it is performed in 2 stages: First, we estimate effects within trials, and then we combine results across trials in a meta-analysis.
One-Stage Meta-Analyses
We performed 1-stage meta-analyses of the pain and function outcomes as a comparison to confirm the validity of the 2-stage analyses.
In a 1-stage analysis, all patient data from all trials are combined simultaneously in a single regression model that is stratified by trial (hence in 1 stage). For ODI, for example, we used a random-effects linear regression model of change in ODI from baseline against treatment received. This model included data at all time points simultaneously, but with a separate treatment effect estimated at each time point. The model therefore does not assume any particular model for changes in effects over time. However, it does assume the same amount of between-patient variation at every time point and the same amount of betweenstudy variation in treatment effects (heterogeneity) at every time point. The model was also stratified according to the trial to which each patient belonged (12) . This model had the following form:
where y ijk is the change from baseline in ODI at time k for patient j in trial i. x ij is a coding for treatment received (1 ϭ rhBMP-2, 0 ϭ ICBG). ␣ ik is the baseline change in score in trial i at time k, ␤ k is the mean difference between rhBMP-2 and ICBG surgery at time k (that is, the treatment effect), and 2 is the heterogeneity in the treatment effect across trials.
For dichotomous outcomes (successful fusion and adverse events), a similar random-effects logistic regression model, also stratified by trial, was used, with the following form (13):
where p ijk is the probability of successful fusion at time k for patient j in trial i, and so ␤ k is the log odds ratio of event (for example, successful fusion). The numbers of events in any particularly adverse event category in any trial at any time points were often small, and some trials had no adverse events in a particular category. In such a situation, where events are rare, 2-stage meta-analyses of RR may be inaccurate because of the corrections required to adjust for trials with no events. For all analyses of adverse events, we therefore used only 1-stage meta-analysis.
Assessment of Heterogeneity
We assessed heterogeneity in all 2-stage meta-analyses by calculating the I 2 statistic for heterogeneity (14).
Exploring Clinical Heterogeneity
We investigated how trial-level and participant-level factors influenced the effectiveness of rhBMP-2 surgery to try to explain any heterogeneity in the meta-analyses.
For trial-level factors, this was achieved by using subgroup analysis. For example, for type of surgery, trials were divided into subgroups according to the surgery type (ALIF, posterior lumbar interbody fusion, or posterior lumbar fusion, anterior cervical discectomy and fusion). Random-effects meta-analyses were conducted within each surgery subgroup category to estimate the effect of rhBMP-2 for each. The results across subgroups were compared by using tests of heterogeneity (for example, to identify any notable differences between surgery types).
For participant-level factors, we used random-effects 1-stage meta-analysis methods (12) . For example, to investigate the effect of age, we took the linear regression model used for the 1-stage analysis described for ODI above and incorporated an age parameter and an interaction term between age and treatment. This extended model had the following form:
where z ij is the initial age of patient j in trial i, and ␥ is the interaction between age and treatment, which measures the extent to which age affects the efficacy of rhBMP-2 surgery. This model is stratified by trial.
Sensitivity Analyses. Some data were missing at some times after surgery because some patients were lost to follow-up or were not available at certain times. To investigate the potential for bias due to such missing data, we performed a multiple imputation analysis for the main pain outcomes and for spinal fusion. This was achieved by performing a regression of the outcome at each time point against the outcome at the previous time point, stratified by trial, using the complete-case data. Where a participant had no recorded outcome at some time point, the predicted outcome from the model and its SE were used to impute 10 possible outcomes, assuming that outcomes were normally distributed. The resulting 10 complete data sets were analyzed and the results averaged to obtain a summary result after imputation.
Multiple Testing. We note that we have performed a large number of analyses for many outcomes at multiple time points. This increases the probability of identifying a significant difference between treatment groups when there is in fact no difference in any specific analysis to above the nominal 5% significance level (that is, that associated with 95% CIs).
We have not performed any corrections for multiple testing because the variation in numbers of outcomes considered and the different numbers of time periods involved in some analyses would mean that any correction would be arbitrary and would make comparisons between outcomes and between main analyses and sensitivity and subgroup analyses difficult.
Statistical Software
The IPD were supplied by Medtronic in SAS format. All data management, data checking, and data extraction for the IPD were performed by using SAS statistical software (SAS Institute, Cary, North Carolina).
Statistical analyses were performed by using the R statistical software package (R Foundation, Vienna, Austria). In particular, 2-stage meta-analyses were conducted by using the meta library in R, and 1-stage analyses were performed by using the lme4 library for multilevel modeling. Forest plots were produced in R by using an in-house package. All other figures were produced in R by using the ggplot library. 
